Ribi ImmunoChem Research Inc. said Tuesday that it has files aregistration statement with the Securities and ExchangeCommission to offer 3 million shares of common stock, plus anadditional 450,000 shares to cover overallotments.
Hambrecht & Quist Inc. is underwriting the offering.
The Hamilton, Mont., company is developing products thatstimulate the immune system to generate a cascade of naturalagents to treat and prevent human disease.
Ribi's stock (NASDAQ:RIBI) closed unchanged Tuesday at $7.63a share.
(c) 1997 American Health Consultants. All rights reserved.